SAN DIEGO--(BUSINESS WIRE)--Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN) Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property. Mr. Koos noted, “In the last 3 months we have made substantial progress in areas we believe will be accretive for our shareholders. It is my belief that our business model is far more balanced and progressive today than we have previously been. The new opportunities on the table for us now should diversify our revenue model and complement each other as the Company grows. We see Entest BioMedical (OTCBB:ENTB) leading the way in expanding the Company’s core business.”
